Manuscripts and Publications

Filters: First Letter Of Last Name is H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
Hussen SA, Harper GW, Bauermeister JA, Hightow-Weidman LB.  2015.  Psychosocial influences on engagement in care among HIV-positive young black gay/bisexual and other men who have sex with men.. AIDS Patient Care STDS. 29(2):77-85.
Hosek SG, Harper GW, Lemos D, Martinez J.  2008.  An Ecological Model of Stressors Experienced by Youth Newly Diagnosed With HIV.. J HIV AIDS Prev Child Youth. 9(2):192-218.
Hosek SG, Green KR, Siberry G, Lally M, Balthazar C, Serrano PA, Kapogiannis B.  2013.  Integrating Behavioral HIV Interventions into Biomedical Prevention Trials with Youth: Lessons from Chicago's Project PrEPare.. J HIV AIDS Soc Serv. 12(3-4)
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Hosek SG, Harper GW, Lemos D, Burke-Miller J, Lee S, Friedman L, Martinez J.  2018.  Project ACCEPT: Evaluation of a Group-Based Intervention to Improve Engagement in Care for Youth Newly Diagnosed with HIV.. AIDS Behav. 22(8):2650-2661.
Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, M Fernández I, Rutledge B, Martinez J, Garofalo R et al..  2013.  The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.. J Acquir Immune Defic Syndr. 62(4):447-56.
Hosek S, Brothers J, Lemos D.  2012.  What HIV-positive young women want from behavioral interventions: a qualitative approach.. AIDS Patient Care STDS. 26(5):291-7.
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
Hosek SG, Lemos D, Harper GW, Telander K.  2011.  Evaluating the acceptability and feasibility of Project ACCEPT: an intervention for youth newly diagnosed with HIV.. AIDS Educ Prev. 23(2):128-44.
Horvath KJ, Lammert S, LeGrand S, Muessig KE, Bauermeister JA.  2017.  Using technology to assess and intervene with illicit drug-using persons at risk for HIV.. Curr Opin HIV AIDS. 12(5):458-466.
Horvath KJ, MacLehose RF, Martinka A, DeWitt J, Hightow-Weidman L, Sullivan P, Amico KR.  2019.  Connecting Youth and Young Adults to Optimize Antiretroviral Therapy Adherence (YouTHrive): Protocol for a Randomized Controlled Trial.. JMIR Res Protoc. 8(7):e11502.
Hightow-Weidman LB, Muessig KE, Bauermeister JA, LeGrand S, Fiellin LE.  2017.  The future of digital games for HIV prevention and care.. Curr Opin HIV AIDS. 12(5):501-507.
Hightow-Weidman L, Muessig K, Claude K, Roberts J, Zlotorzynska M, Sanchez T.  2020.  Maximizing Digital Interventions for Youth in the Midst of Covid-19: Lessons From the Adolescent Trials Network for HIV Interventions. AIDS Behav.
Hightow-Weidman LB, Muessig K, Rosenberg E, Sanchez T, LeGrand S, Gravens L, Sullivan PS.  2018.  University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development.. JMIR Res Protoc. 7(8):e10365.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N et al..  2017.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2013.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.
Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB.  2012.  Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
Havens PL, Hazra R.  2015.  Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.. Pediatr Infect Dis J. 34(4):406-8.
Harper GW, Jadwin-Cakmak L, Cherenak E, Wilson P.  2019.  Critical Consciousness-Based HIV Prevention Interventions for Black Gay and Bisexual Male Youth.. Am J Sex Educ. 14(1):109-133.
Harper GW, Brodsky A, Bruce D.  2012.  What's Good about Being Gay?: Perspectives from Youth. J LGBT Youth. 9(1):22-41.
Harper GW, Neubauer LC, Bangi AK, Francisco VT.  2008.  Transdisciplinary research and evaluation for community health initiatives.. Health Promot Pract. 9(4):328-37.
Harper GW, Bruce D, Hosek SG, M Fernández I, Rood BA.  2014.  Resilience processes demonstrated by young gay and bisexual men living with HIV: implications for intervention.. AIDS Patient Care STDS. 28(12):666-76.
Harper GW, Tyler ATimmons, Bruce D, Graham L, Wade RM.  2016.  Drugs, Sex, and Condoms: Identification and Interpretation of Race-Specific Cultural Messages Influencing Black Gay and Bisexual Young Men Living with HIV.. Am J Community Psychol. 58(3-4):463-476.
Harper GW, Fernandez IM, Bruce D, Hosek SG, Jacobs RJ.  2013.  The role of multiple identities in adherence to medical appointments among gay/bisexual male adolescents living with HIV.. AIDS Behav. 17(1):213-23.
Harper GW, Serrano PA, Bruce D, Bauermeister JA.  2016.  The Internet's Multiple Roles in Facilitating the Sexual Orientation Identity Development of Gay and Bisexual Male Adolescents.. Am J Mens Health. 10(5):359-76.
Harper GW, Lemos D, Hosek SG.  2014.  Stigma reduction in adolescents and young adults newly diagnosed with HIV: findings from the Project ACCEPT intervention.. AIDS Patient Care STDS. 28(10):543-54.
Harper GW, Jadwin-Cakmak LA, Popoff E, Campbell BAnne, Granderson R, Wesp LM.  2019.  Transgender and Other Gender-Diverse Youth's Progression Through the HIV Continuum of Care: Socioecological System Barriers.. AIDS Patient Care STDS. 33(1):32-43.